WASHINGTON (Reuters) – The U.S. Federal Trade Commission said on Friday that it had approved generic drugmaker Mylan NV’s MYL.O planned purchase of Pfizer’s PFE.N Upjohn, subject to conditions.
The proposed transaction was announced in July.
To win approval for the deal, the companies agreed to sell assets related to several Upjohn products, including spironolactone HCTZ tablets used to treat high blood pressure and edema as well as Mylan’s eplerenone tablets, another high blood pressure medicine Read more. Reuters news.
